Articles in this section

• Updated Hepatitis C Treatment Guidelines

  

  Geneva - July 2018
  The World Health Organization released the updated Guidelines for the Care and Treatment of Persons Diagnosed with Chronic Hepatitis C Virus Infection. They follow and update the screening and care section of the WHO Guidelines for the screening, care and treatment of (...) More

  8 November 2018

• Updated Training Manual for Treatment Advocates: Hepatitis C Virus & Coinfection with HIV

  

  This Training Manual was designed and updated in February 2018 by Treatment Action Group (TAG), an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine, and a cure for HIV, tuberculosis, and hepatitis C virus.
  The purpose (...) More

  22 February 2018

• Genotypes Fact Sheet

  A genotype is a way to put the hepatitis C virus (HCV) into categories based on similar genes. It’s important to know and understand HCV genotypes because different genotypes respond differently to medicines that treat and cure HCV.
  HCV has six genotypes, labeled 1 through 6. There are also (...) More

  30 April 2017

• Viekira XR and Technivie Fact Sheet

  Viekira XR is a combination of hepatitis C virus–fighting drugs (paritaprevir/ritonavir/ombitasvir and dasabuvir) that block different steps of the virus life cycle. In the United States, Viekira XR is approved for people with hepatitis C genotype 1 who are over 18 years old. Viekira XR was (...) More

  30 April 2017

• Epclusa Fact Sheet

  Epclusa is a fixed-dose combination of two HCV-fighting drugs (sofosbuvir and velpatasvir) in one pill. In the United States, Epclusa is approved for people with all hepatitis C genotypes (1–6) who are 18 years of age and older. The fact sheet provides information about this treatment (...) More

  30 April 2017